INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE is a distinguished publication in the field of Psychiatry and Mental Health, published by TAYLOR & FRANCIS LTD in the United Kingdom. With an impressive 2023 impact factor that places it in the Q2 category among its peers, this journal is an essential resource for researchers, clinicians, and students dedicated to advancing mental health practices and understanding psychiatric disorders. Covering topics from clinical studies to innovative treatment methodologies, the journal welcomes original research, reviews, and case studies that contribute valuable insights into clinical practice. Accessible without any open access restrictions, the journal has been a pivotal platform since its inception in 1997, facilitating knowledge exchange in the field up to 2024. As evidenced by its notable Scopus ranking within the top 73rd percentile of Psychiatry and Mental Health, it remains committed to impacting clinical practices significantly.

The American Journal of Psychiatry, published by the renowned American Psychiatric Publishing, Inc., stands as a premier platform in the field of Psychiatry and Mental Health. With its inaugural edition released in 1945, this esteemed journal has consistently provided a wealth of knowledge, shaping the landscape of psychiatric research and practice globally. Notably, in the latest 2023 Scopus rankings, it achieved an impressive rank of #7 out of 567 journals in its category, placing it in the top 2% percentile, indicative of its substantial impact within the field. The journal is committed to publishing high-quality, peer-reviewed original research, clinical studies, and reviews that advance psychiatric knowledge and treatment options. Although it does not currently offer open access, its contributions are vital for researchers, clinicians, and students dedicated to improving mental health care and understanding complex mental health disorders. As an essential resource, it continues to foster scholarly communication among professionals who are at the forefront of psychiatric science.

Neurosciences is a premier academic journal dedicated to the exploration of neurological and psychiatric disorders, fostering an innovative exchange of ideas and research findings in these critical fields. Published by the Riyadh Armed Forces Hospital in Saudi Arabia, this interdisciplinary journal has consistently contributed to the advancement of knowledge since its inception in 2002 and is set to continue through 2024. With an ISSN of 1319-6138 and E-ISSN of 1658-3183, it is recognized for its emphasis on clinically relevant research in neurology and psychiatry, boasting a 2023 classification in the Q3 tier of both categories. Neurosciences encourages submissions that offer novel insights into mental health and neurological conditions, positioning itself as a vital resource for researchers, healthcare professionals, and students alike. Despite being unlisted as an open-access journal, it remains a respected outlet for peer-reviewed content, with Scopus rankings that highlight its growing influence within the scientific community. This journal serves as an essential platform for disseminating significant research that addresses the intricacies of the human brain and behavior.

Behavioural Pharmacology is a distinguished academic journal published by Lippincott Williams & Wilkins, focusing on the intricate relationship between pharmacology, psychiatry, and behavioral science. With an ISSN of 0955-8810 and an E-ISSN of 1473-5849, this journal serves as a vital platform for researchers and professionals dedicated to exploring the pharmacological mechanisms underlying behavior and mental health. Operating with a robust track record since its inception in 1992, it has established itself in the academic community, as reflected by its Q3 rankings in both the pharmacology and psychiatry categories for 2023. Additionally, the journal holds a credible position in Scopus rankings, with a percentile ranking indicative of significant contributions to the fields of pharmacology and psychiatry. Aimed at advancing knowledge and disseminating research in the behavioral pharmacology domain, this journal is an essential resource for students, researchers, and clinical professionals seeking to stay at the forefront of this rapidly evolving field. While it is not an open access journal, the rich content and research findings published here continue to foster collaboration and innovation within the community, making it a crucial reference point for current and future studies.

Psychiatry International, published by MDPI, is a dynamic and open-access journal dedicated to advancing the field of psychiatry and mental health. Since its inception in 2020, this journal has emerged as a vital platform for the dissemination of innovative research and impactful insights across various subdisciplines, encompassing psychiatric nursing, general medicine, and neuroscience. With an E-ISSN of 2673-5318, Psychiatry International facilitates accessibility to research findings and fosters collaboration among researchers, healthcare professionals, and academics worldwide. The journal's alignment with modern Open Access principles reflects its commitment to enhancing the visibility and reach of psychiatric research. Despite being relatively new, it has demonstrated a promising standing in Scopus rankings, positioning itself within the top quartile for Nursing (Psychiatric Mental Health) and showing potential for growth in other related categories. By encouraging submissions that address the latest developments and challenges in mental health, Psychiatry International aims to catalyze progress in mental health awareness and intervention strategies, making it an essential resource for anyone engaged in the field.

Psychiatry and Clinical Psychopharmacology, an open-access journal published by AVES since 2017, is dedicated to advancing the fields of psychiatric medicine and psychopharmacology. With an ISSN of 2475-0573 and an E-ISSN of 2475-0581, this journal aims to provide a platform for disseminating innovative research and clinical findings relevant to mental health professionals and researchers. Although it currently holds a Q3 ranking in Pharmacology (medical) and a Q4 ranking in Psychiatry and Mental Health according to the 2023 category quartiles, the journal has established itself as a significant contributor to evolving discussions in these critical fields. Based in the United Kingdom, the journal encompasses diverse topics, ranging from pharmacological treatments to novel therapeutic approaches in psychiatry, thereby appealing to a broad audience of clinicians, scientists, and students. The open-access model ensures that all research is readily available, fostering an environment of collaboration and knowledge-sharing as the journal converges until 2024 to encompass the latest advancements in both pharmacology and clinical psychopharmacology.

EUROPEAN NEUROPSYCHOPHARMACOLOGY, published by Elsevier, is a prestigious academic journal that serves as a cornerstone in the field of neuropsychopharmacology, embracing multidisciplinary research at the intersection of neuroscience, psychiatry, and pharmacology. Since its establishment in 1990, this journal has consistently delivered cutting-edge research and reviews that drive forward our understanding of central nervous system disorders and their treatment. With an impressive impact factor and ranked in the Q1 category for several disciplines, including Biological Psychiatry and Neurology, it attracts submissions from leading researchers globally. The journal’s Scopus rankings reflect its significant influence, ranking in the top echelons across various categories such as Medicine and Neuroscience. While the journal maintains subscription access, readers are encouraged to explore the breadth of important findings that contribute to advancements in treatment options and improve patient care. EUROPEAN NEUROPSYCHOPHARMACOLOGY not only supports the dissemination of pivotal research but also fosters collaboration and dialogue within the scientific community, making it an essential resource for researchers, clinicians, and students dedicated to the complexities of brain health.

NEUROPHARMACOLOGY, published by PERGAMON-ELSEVIER SCIENCE LTD, is a prestigious journal in the field of neuroscience and pharmacology, with a distinguished history dating back to 1962. With an ISSN of 0028-3908 and an E-ISSN of 1873-7064, the journal serves as a dynamic platform for the latest research that explores the intricate relationships between pharmacological agents and neural processes. Positioned in the Q1 quartile in both Cellular and Molecular Neuroscience and Pharmacology, it is recognized for its significant impact in the scientific community, boasting Scopus rankings of #36 in Pharmacology and #16 in Cellular and Molecular Neuroscience, underscoring its excellence and relevance. Although not an open access publication, its contributions are pivotal for researchers, professionals, and students sought to understand the complexities of neuropharmacological interactions. The journal aims to disseminate groundbreaking research findings, reviews, and perspectives that expand the frontiers of knowledge in the fields, making it an essential resource for anyone involved in neuroscience and pharmacology research.

Biological Psychiatry is a premier journal dedicated to advancing the understanding of the biological underpinnings of psychiatric disorders. Published by Elsevier Science Inc, this esteemed journal is recognized globally for its rigorous peer-reviewed research and contributes significantly to the field of biological psychiatry. With an impressive impact factor that places it in Q1 of its category and ranks 3rd out of 51 in Neuroscience Biological Psychiatry, it reflects the journal's strength in disseminating high-quality findings that push the boundaries of knowledge. Since its inception in 1969, the journal has undergone continuous evolution, aiming to integrate biological and clinical perspectives to optimize the understanding of mental health conditions. Although it does not offer open access, Biological Psychiatry serves as a critical resource for researchers, practitioners, and students, offering insights that influence both theoretical frameworks and practical applications in the realm of psychiatric science.

NEUROPSYCHOBIOLOGY, published by KARGER, is a leading academic journal that has been at the forefront of exploring the intricate relationships between neuroscience and psychological processes since its inception in 1975. With both an ISSN of 0302-282X and an E-ISSN of 1423-0224, the journal is renowned for its rigorous peer-reviewed articles and significant contributions to the fields of Biological Psychiatry, Neuropsychology, and Physiological Psychology. Its impact is reflected in its esteemed Scopus rankings, standing out in the 92nd and 81st percentiles in their respective categories. With a commitment to advancing understanding in mental health and neurological science, NEUROPSYCHOBIOLOGY is classified in the Q3 and Q1 quartiles, making it a vital resource for researchers, clinicians, and students alike. Based in Switzerland, the journal embraces a holistic approach to psychological research, bridging gaps between theoretical frameworks and practical applications, thus promoting impactful advancements in the understanding of the human mind.
Explore the latest findings and theories with NEUROPSYCHOBIOLOGY, where your work can contribute to the evolving landscape of neuropsychological studies.